Thromboelastography: Difference between revisions
Jump to navigation
Jump to search
Thromboelastography |
m SIze |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
}} | }} | ||
==Interpretation== | ==Interpretation== | ||
[[Image:Thromboelastography parameters.png|thumb|330px|Normal thromboelastogram with parameters.]] | |||
Parameters derived from thromboelastography are mainly:<ref name="pmid32988649">{{cite journal| author=Tyler PD, Yang LM, Snider SB, Lerner AB, Aird WC, Shapiro NI| title=New Uses for Thromboelastography and Other Forms of Viscoelastic Monitoring in the Emergency Department: A Narrative Review. | journal=Ann Emerg Med | year= 2021 | volume= 77 | issue= 3 | pages= 357–366 | pmid=32988649 | doi=10.1016/j.annemergmed.2020.07.026 | pmc= | doi-access=free }} </ref> | |||
* '''R time''': Time to initial clot formation (that is, amplitude deviation from baseline) | |||
* '''K time''': Time from initial clot formation until reaching 20 mm in amplitude | |||
* '''Alpha angle (α)''': Angle between the baseline at initial clot formation, and a tangent line that intersects the tracing curve. | |||
* '''Maximum amplitude (MA)''': Maximum deviation of tracing to baseline. | |||
* '''A<sub>30</sub>''': Amplitude 30 minutes after reaching maximum amplitude. | |||
Following are examples of thromboelastography patterns and recommended treatments.<ref>{{cite journal| author=Collins S, MacIntyre C, Hewer I| title=Thromboelastography: Clinical Application, Interpretation, and Transfusion Management. | journal=AANA J | year= 2016 | volume= 84 | issue= 2 | pages= 129–34 | pmid=27311154 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27311154 }}</ref><ref>{{cite journal| author=Kreitzer NP, Bonomo J, Kanter D, Zammit C| title=Review of Thromboelastography in Neurocritical Care. | journal=Neurocrit Care | year= 2015 | volume= 23 | issue= 3 | pages= 427–33 | pmid=26275677 | doi=10.1007/s12028-015-0187-9 | pmc= | s2cid=29854774 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26275677 }}</ref> | Following are examples of thromboelastography patterns and recommended treatments.<ref>{{cite journal| author=Collins S, MacIntyre C, Hewer I| title=Thromboelastography: Clinical Application, Interpretation, and Transfusion Management. | journal=AANA J | year= 2016 | volume= 84 | issue= 2 | pages= 129–34 | pmid=27311154 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27311154 }}</ref><ref>{{cite journal| author=Kreitzer NP, Bonomo J, Kanter D, Zammit C| title=Review of Thromboelastography in Neurocritical Care. | journal=Neurocrit Care | year= 2015 | volume= 23 | issue= 3 | pages= 427–33 | pmid=26275677 | doi=10.1007/s12028-015-0187-9 | pmc= | s2cid=29854774 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26275677 }}</ref> | ||
{|class=wikitable | {|class=wikitable | ||
| Line 18: | Line 26: | ||
| Thrombosis || [[File:Thromboelastography in thrombosis.png|170px]] || Anticoagulant | | Thrombosis || [[File:Thromboelastography in thrombosis.png|170px]] || Anticoagulant | ||
|- | |- | ||
| Primary fibrinolysis || [[File:Thromboelastography in primary fibrinolysis.png|170px]] || Antifibrinolytics or | | Primary fibrinolysis || [[File:Thromboelastography in primary fibrinolysis.png|170px]] || Antifibrinolytics or tranexamic acid | ||
|- | |- | ||
| Secondary fibrinolysis || [[File:Thromboelastography in secondary fibrinolysis.png|170px]] || Treating | | Secondary fibrinolysis || [[File:Thromboelastography in secondary fibrinolysis.png|170px]] || Treating disseminated intravascular coagulation | ||
|} | |} | ||
{{Bottom}} | {{Bottom}} | ||